Qulipta
$800.00
Qulipta is an oral medication prescribed to prevent episodic migraine attacks in adults.
Qulipta (generic name: atogepant) is an oral medication prescribed to prevent episodic migraine attacks in adults. It is an oral form of calcitonin gene-related peptide (CGRP) monoclonal antibodies that were previously only available as injectables. It was first approved for medical use in the US in September 2021 and is only available under the brand name. Dosage Atogepant is approved for dosing at levels of 10, 30, or 60 mg daily, as prescribed by the doctor.
Brand Manufacturer: Abbvie
Side Effects: Qulipta may cause some mild side effects, such as nausea; constipation; decreased appetite; fatigue or sleepiness. If these persist or get worse, a healthcare professional should be consulted.
Indication: Qulipta (atogepant) is a daily oral treatment for migraines. It offers patients an alternative therapy to injectable or infusion monoclonal antibody treatments in cases where they have shown poor tolerance to alternative non-specific migraine medications.
Reviews
Write a review
The product has no reviews
Leave your review
